Prognostic value of Ki-67 compared to S-phase fraction in axillary node-negative breast cancer.

The primary purpose of this study was to evaluate the prognostic significance of Ki-67, a cell proliferation-associated antigen, in a large group (n = 674) of axillary node-negative breast cancer cases with long-term follow-up and to correlate Ki-67 antigen expression with S-phase fraction. Ki-67 immunostaining was assessed both semiquantitatively and quantitatively. The statistical analysis focused on agreement between methods of Ki-67 quantification, agreement between Ki-67 and S-phase fraction, associations between Ki-67 and other clinical variables, and prognostic value of Ki-67. There was excellent agreement between the two methods of Ki-67 assessment (Spearman rank correlation, rsp = 0.91; P = 0.0001; n = 674) but only weak correlation between either semiquantitative or quantitative Ki-67 and S-phase fraction (rsp = 0.12 and rsp = 0.15, respectively). Ki-67 (overall median, 2%) was independent of tumor size and modestly related to other measures of tumor aggressiveness. Using a cutpoint of 5% (percentage of tumor cells), cases with high Ki-67 exhibited a significantly shorter disease-free survival (Padj = 0.004). In multivariate analysis, high Ki-67 was associated with a 1.8-fold increased risk of recurrence (P = 0.001). In the subgroup with S-phase data, the adjusted relative risk (hazard ratio, 1.9; P = 0.02) was unchanged by inclusion of S phase in the model. This suggests that Ki-67 provides significant independent prognostic information in addition to that contained in tumor size and S-phase fraction.

[1]  A. Cnaan,et al.  Proliferation markers in breast carcinoma. , 1996, American journal of clinical pathology.

[2]  G. Clark,et al.  Practical p-value adjustment for optimally selected cutpoints. , 1996, Statistics in medicine.

[3]  P. Hall,et al.  Adjuvant Therapy of Node-Negative Breast Cancer , 1995, The Annals of pharmacotherapy.

[4]  R. Silvestrini.  Cell kinetics: prognostic and therapeutic implications in human tumours , 1994 .

[5]  P. Boracchi,et al.  Cell kinetics in human breast cancer: Comparison between the prognostic value of the cytofluorimetric S‐phase fraction and that of the antibodies to Ki‐67 and PCNA antigens detected by immunocytochemistry , 1994, International journal of cancer.

[6]  J. Gerdes,et al.  The cell proliferation-associated antigen of antibody Ki-67: a very large, ubiquitous nuclear protein with numerous repeated elements, representing a new kind of cell cycle-maintaining proteins , 1993, The Journal of cell biology.

[7]  S. Nordling,et al.  Prognostic value of Ki-67 immunolabelling in primary operable breast cancer. , 1993, British Journal of Cancer.

[8]  P. Lampertico,et al.  Proliferation index as a prognostic marker in breast cancer , 1993, Cancer.

[9]  W. McGuire,et al.  Immunohistochemistry on Histological Sections from Small (50 mg) Samples of Pulverized Breast Cancer , 1993 .

[10]  T. Venesio,et al.  Cell proliferation of breast cancer evaluated by anti-BrdU and anti-Ki-67 antibodies: its prognostic value on short-term recurrences. , 1993, European journal of cancer.

[11]  J. Gerdes,et al.  Immunohistological detection of tumour growth fraction (Ki-67 antigen) in formalin-fixed and routinely processed tissues. , 1992, The Journal of pathology.

[12]  C. Hitchcock.  Ki-67 staining as a means to simplify analysis of tumor cell proliferation. , 1991, American journal of clinical pathology.

[13]  J. Gerdes,et al.  Immunobiochemical and molecular biologic characterization of the cell proliferation-associated nuclear antigen that is defined by monoclonal antibody Ki-67. , 1991, The American journal of pathology.

[14]  S. Veronese,et al.  Detection of Ki-67 proliferation rate in breast cancer. Correlation with clinical and pathologic features. , 1991, American journal of clinical pathology.

[15]  S. Chevillard,et al.  Ki67 index and S-phase fraction in human breast carcinomas. Comparison and correlations with prognostic factors. , 1990, American journal of clinical pathology.

[16]  M. Fernö,et al.  Indicators of prognosis in node-negative breast cancer. , 1990, The New England journal of medicine.

[17]  P. Grambsch,et al.  Martingale-based residuals for survival models , 1990 .

[18]  O. Kallioniemi,et al.  Evaluation of cell proliferation in breast carcinoma. Comparison of Ki‐67 immunohistochemical study, DNA flow cytometric analysis, and mitotic count , 1990, Cancer.

[19]  K. Weber,et al.  Vimentin is preferentially expressed in human breast carcinomas with low estrogen receptor and high Ki-67 growth fraction. , 1990, The American journal of pathology.

[20]  I. Nenci,et al.  Assessment of proliferative rate of breast cancer by Ki-67 monoclonal antibody. , 1990, Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc.

[21]  J W Bacus,et al.  Biological grading of breast cancer using antibodies to proliferating cells and other markers. , 1989, The American journal of pathology.

[22]  J. Isola,et al.  Proliferative activity and steroid receptors determined by immunohistochemistry in adjacent frozen sections of 102 breast carcinomas. , 1989, Archives of pathology & laboratory medicine.

[23]  J. Gerdes,et al.  Relationship of cytosolic estrogen and progesterone receptor content and the growth fraction in human mammary carcinomas. , 1989, Cancer research.

[24]  A. Leong,et al.  The relationship between growth fractions and oestrogen receptors in human breast carcinoma, as determined by immunohistochemical staining , 1989, The Journal of pathology.

[25]  I. Ellis,et al.  Ki67 immunostaining in primary breast cancer: pathological and clinical associations. , 1989, British Journal of Cancer.

[26]  G M Clark,et al.  Prediction of relapse or survival in patients with node-negative breast cancer by DNA flow cytometry. , 1989, The New England journal of medicine.

[27]  A. Chott,et al.  K-67 Immunoreactivity in Breast Carcinomas in Relation to Transferrin Receptor Expression, Estrogen Receptor Status and Morphological Criteria , 1989 .

[28]  J. Meyer,et al.  Thymidine labeling index and Ki-67 growth fraction in lesions of the breast. , 1989, The American journal of pathology.

[29]  A. Chott,et al.  Ki-67 immunoreactivity in breast carcinomas in relation to transferrin receptor expression, estrogen receptor status and morphological criteria. An immunohistochemical study. , 1989, Oncology.

[30]  L. Andrac,et al.  Multiparametric evaluation (SAMBA) of growth fraction (monoclonal Ki67) in breast carcinoma tissue sections. , 1988, Cancer research.

[31]  J. Meyer,et al.  Thymidine labeling index, flow cytometric S-phase measurement, and DNA index in human tumors. Comparisons and correlations. , 1988, American journal of clinical pathology.

[32]  W. McGuire,et al.  DNA flow cytometry and prognostic factors in 1331 frozen breast cancer specimens , 1988, Cancer.

[33]  H. Stein,et al.  Growth fractions and estrogen receptors in human breast cancers as determined in situ with monoclonal antibodies. , 1987, The American journal of pathology.

[34]  W. Franklin,et al.  Assessment of tumor cell kinetics by immunohistochemistry in carcinoma of breast , 1987, Cancer.

[35]  W Heidenreich,et al.  The correlation of growth fractions with histologic grading and lymph node status in human mammary carcinoma , 1987, Cancer.

[36]  H Stein,et al.  Growth fractions in breast cancers determined in situ with monoclonal antibody Ki-67. , 1986, Journal of clinical pathology.

[37]  M. Daidone,et al.  Cell kinetics as a prognostic marker in node‐negative breast cancer , 1985, Cancer.

[38]  D. Cox,et al.  Analysis of Survival Data. , 1985 .

[39]  H Stein,et al.  Cell cycle analysis of a cell proliferation-associated human nuclear antigen defined by the monoclonal antibody Ki-67. , 1984, Journal of immunology.

[40]  M. Tubiana,et al.  The long‐term prognostic significance of the thymidine labelling index in breast cancer , 1984, International journal of cancer.

[41]  M. M. McCrate,et al.  Prediction of early course of breast carcinoma by thymidine labeling , 1983, Cancer.

[42]  Johannes Gerdes,et al.  Production of a mouse monoclonal antibody reactive with a human nuclear antigen associated with cell proliferation , 1983, International journal of cancer.

[43]  M. Tubiana,et al.  Kinetic parameters and the course of the disease in breast cancer , 1981, Cancer.

[44]  R. Silvestrini,et al.  Cell proliferation and its relationship to clinical features and relapse in breast cancers. , 1981, Cancer.

[45]  J. Meyer,et al.  Relationships of S-phase fraction of breast carcinoma in relapse to duration of remission, estrogen receptor content, therapeutic responsiveness, and duration of survival. , 1980, Cancer research.

[46]  J. Meyer,et al.  Advanced stage and early relapse of breast carcinomas associated with high thymidine labeling indices. , 1979, Cancer research.

[47]  W. McGuire,et al.  Measurement of progesterone receptor in human breast cancer biopsies. , 1979, Cancer research.

[48]  M. DeLaGarza,et al.  Evaluation of estrogen receptor assays in human breast cancer tissue. , 1977 .

[49]  J. Fleiss,et al.  Statistical methods for rates and proportions , 1973 .